The U.S. cann-a-bis industry is growing at an unparalleled pace. Sales for 2021 are estimated to finish at $31 billion, an increase of 41% over 2020. (4) And yet, despite this positive sales growth, cann-a-bis stocks slumped in the second half of 2021. Think about it. Sales up, revenues up, growth flourishing – stock prices down? This screams opportunity and Flora Growth Corp (NASDAQ: FLGC) could be a perfect example. In fact, not one, but two Wall Street analysts believe Flora could be unreasonably undervalued.
Analysts believe that Flora Growth Corp. (NASDAQ:FLGC) stock could be surprisingly undervalued with a 5x upside potential (1). FLGC is now producing High-T-H-C crude oil in their EU-GMP compliant Cosechemos facility, unlocking a major revenue opportunity in the $16.47 billion global medical cann-a-bis market.(2)(3). FLGC’s revenue projections for 2022 of $35-45M have ballooned higher compared to projections from 2021. Plus, the company has cushioned its cash balance by securing $34.5M in financing (4)(5).
FLGC is piling up major retail and distribution agreements:
– Walmart.com – Macy’s
– Tonino – FLGC will distribute food products to Colombia-based Tropi (6)(7)(8)(9)
FLGC strengthened its U.S. presence by acquiring Vessel Brand Inc. an industry leader in cann-a-bis consumer technology with trailing 12-months revenue of $6.6M and year-over-year growth of 90% (10).
Click HERE to read more about FLGC.
Other companies in Flora Growth’s space includes: Olaplex Hldgs (NASDAQ:OLPX), Revlon (NYSE:REV), Herbalife Nutrition (NYSE:HLF), Honest Co (NASDAQ:HNST) and Natural Health Trends (NASDAQ:NHTC). We believe that Flora is attractively valued relative to peers based on its low-cost structure, strong brand portfolio, and expanding global distribution.
Source 2: https://tinyurl.com/3yzndbdc
Source 3: https://tinyurl.com/3cscums2
Source 8: https://tinyurl.com/ynu8u7t4
Source 9: https://tinyurl.com/yck2dn9r
Disclaimers: WallStreetPR is merely distributing information provided by BullzeyeMedia LLC. WallStreetPR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by BullzeyeMedia LLC is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall WALLSTREETPR be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by WALLSTREETPR ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. WallStreetPR. strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, WALLSTREETPR, ., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting WallStreetPR.com/Disclaimer. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.